Flot.bio x Philip Hemme

Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting.

The cell therapy master outlines his central role in bringing two first‑in‑class cell therapies to patients: Kymriah, the first approved CAR‑T, and Ebvallo, the first approved allogeneic T‑cell therapy.

We also explore his new position as an operating partner at Jeito and how we need to work harder to find Europe’s hidden biotech gems.

-----------------------------------------------------------------------

Get expe...

Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in Vienna after he left Evotec and went on a sabbatical in 2024. We talk about his new missions as FairJourney CEO and founder of WLAN Holdings, and discuss the global CDMO scene and Europe’s competitivity in biotech.And while it's still early days yet, we find out AI will transform the way we work in biopharma going forward, with new generations of companies shaping their business models around it.

⭐️ ABOUT THE SP...

Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially in the US, and how it is impacting the industry.⭐️ ABOUT THE SPEAKERA veteran in the development of more than ten vaccines, Thomas has spent over 30 years in the vaccine space and has served in senior roles at the companies Intercell, Novartis and Chiron. Thomas was with Intercell since 2006 and was the CEO when the company merged with Vivalis to form Valneva in 2013.🔗 LINKS MENTIONED

When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes.

Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a remarkable biotech turnaround.

Marc discusses the processes involved in executing the phase 3 trial that beat even Abivax’s own phase 2 data. He also talks about France’s biotech ecosystem and the importance of having the right team.

⭐️ ABOUT THE SPEAKER

Marc de Garidel joined Abivax as CEO in 2023. Prior to this, he led two biotech...

As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to partner with giants like Johnson & Johnson, and how Laurent’s leadership style has evolved over his long tenure.

⭐️ ABOUT THE SPEAKERLaurent Lévy co-founded Nanobiotics in 2003 and has served as CEO ever since. Before this, he worked in a variety of roles with companies including Altran Technologies, Valbiotis and Sanofi.He has a doctorate in nanomaterials-focused physical chemistry from the Pierre and...

As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR-T therapies, and manufacturing.

Philip sits down with co-founder Gerrit Sitters to discuss the company’s trajectory, the cyclic biotech investment market, and lessons from spinning the firm out from Vrije Universiteit Amsterdam.

---Explore how LUMICKS' technology helps develop biologics and cell therapies with unique cell avidity data — http://bit.ly/lumicks---

⭐️ ABOUT THE SPEAKER<...

We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui.

Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produced in the milk of transgenic rabbits. He also talks about the growth of Pharming from a protein therapy-focused biotech into a European multi-asset heavyweight, with a market cap of at least €800 million.

⭐️ ABOUT THE SPEAKER

Fabrice Chouraqui has been the CEO of Pharming Group since March 2024. Prior to this, he was a...

Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin grafts in patients with severe burns. She also explains the decentralization of tissue manufacturing with automation and the need for perseverance as a founder and CEO.

---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path...

Philip meets up with Dragan Grabulovski, CEO of the startup Araris, at Lake Zurich to chat about the company’s work with antibody-drug conjugates (ADCs).They talk about Araris’ huge $400M upfront buyout by Taiho Pharma of Japan, Dragan’s extensive history as a biotech entrepreneur, and Araris’ vision to replace chemotherapy with ADCs.⭐️ ABOUT THE SPEAKERDragan Grabulovski is a co-founder of the startup Araris and became CEO in 2023. He previously worked as a biotech consultant and startup coach in Switzerland. He co-founded the biotech company Covagen in 2007, which was acquired by Johnson & Johnson in 2014. Dragan has a Master’s degree and a...

On a trip to Basel, Switzerland, Philip catches up with Stefano Portolano, CEO of the European firm Azafaros. They chat about Azafaros’ massive $147M Series B round in May 2025, which is being used to develop a small molecule treatment for rare diseases known as lysosomal storage disorders.Stefano also explains how rare diseases went in and out of fashion with big pharma, the revival of small molecule drugs relative to gene therapies and biologics, and his extensive experience in big biotech firms.⭐️ ABOUT THE SPEAKERWith more than 20 years of experience in orphan diseases under his belt, Stefano Portolano joined Azafar...

We chat about longevity with Alex Zhavoronkov, CEO and founder of the artificial intelligence (AI) specialist Insilico Medicine.

Born in Latvia, Alex founded Insilico in 2014, with the company raising a huge $110M Series E round this year.

Alex gives us a tour of Insilico’s sprawling pipeline, a blunt rundown of the competitive landscape in AI drug development, and explains how Insilico is navigating the huge challenges faced by longevity-focused startups.

⭐️ ABOUT THE SPEAKER

Alex founded Insilico in 2014 after serving in senior roles at ATI Technologies, NeuroGNeuroinformatics, and the Bi...

We jet off to Central London to meet Robin Carr, CEO of Myricx Bio, a startup developing antibody-drug conjugates (ADCs) to treat cancer.

The team’s idea – using a novel ADC payload inhibiting molecules called N-myristoyltransferases (NMTs) – helped them to bag an impressive £90M ($114M) Series A round in 2024.

Robin outlines Myricx’s journey from small molecule antivirals to the booming market of cancer ADCs, and how the transition from big pharma to biotech has been an energising experience for him.

--------------------

This episode is sponsored by Kadans. Learn more about Kadans’ L...

We dive into the world of cutting-edge cancer treatments with Aino Kalervo, Chief Operating Officer of TILT Biotherapeutics and occasional tennis legend in her spare time.TILT recently closed a $25M series B round, backed by leading Finnish investors, to finance the clinical development of its oncolytic virus candidate to supercharge cancer immunotherapies.We also explore the challenging space of oncolytic viruses and the untapped potential of biotech innovation in Finland.______For transparency, this episode has been sponsored by TILT.______⭐️ ABOUT THE SPEAKERAino Kalervo is the Chief Operating Officer of TILT Biotherapeutics, responsible for fundraising and business development. She has...

Fresh after leading Calliditas Therapeutics through a $1.1B acquisition, Renee Aguiar-Lucander takes us through her new CEO role at Hansa Biopharma 🇸🇪.We learn how Hansa is commercialising Idefirix, its lead product for improving outcomes in kidney transplantation. We also cover the hot area of immunology, the behind-the-scenes story behind Calliditas’ takeover and the complex world of biotech financing.-----Launching a biotech startup? Grab your Biotech Starter Kit through Merck’s New Lab Starter Program and get the tools and support you need from day one: https://bit.ly/biotech-starter-kit----⭐️ ABOUT THE SPEAKERRenee Aguiar-Lucander became the CEO of Hansa Biopharma in April 2025...

We’re with Stephane Bancel, CEO of the US mRNA giant Moderna. The company’s 15-year trajectory has taken it from the startup seed stage to a commercial heavyweight with three mRNA-based products in the market 🧬

We go in-depth into Stephane’s leadership style and background before delving into Moderna’s research and the evolution of the mRNA space.

⭐️ ABOUT THE SPEAKER

Stéphane Bancel joined mRNA therapeutics company Moderna as CEO in 2011 and led its efforts to develop a commercial COVID-19 vaccine during the global pandem...

We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of Ohtuvayre, Verona’s drug. We also discuss the British roots of the company and why execution is the most important in biotech.⭐️ ABOUT THE SPEAKERChris Martin joined Verona Pharma as their COO in 2020. He’s at the helm of Verona’s commercial strategy, driving the company’s progress in respiratory medi...

We’re online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This episode is sponsored by CUTISS, the only TechBio company in the advanced clinical stage of developing skin tissue therapies. Learn how you can support CUTISS on its path to Series C success: https://bit.ly/flotbio-cutiss---⭐️ ABOUT THE SPEAKERIn 2023, Daniela Marino was named as one of the 30 Rising Leaders in the heal...

We’re in Barcelona 🇪🇸  with Joris Pezzini from Alira Health to discuss the hottest biotech insights right now, including obesity, I&I, radiopharmaceuticals and ADCs.

---

This episode is sponsored by Alira Health, an advisor and clinical development partner for life sciences companies. Learn more at https://bit.ly/alirahealth-flotbio-1

---

⭐️ ABOUT THE SPEAKER

Joris Pezzini has been in the biotech world for over 15 years. Before joining Alira Health in 2019, he had worked in some top pharma and biotech companies across the US, UK and France...

We’re in Copenhagen 🇩🇰 with Christophe Bourdon, the CEO who turned a 116-year-old biopharma company from the brink of failure to success.We discuss the lessons behind the turnaround, innovation in dermatology, especially biologicals and I&I, and living in eight different countries.

⭐️ ABOUT THE SPEAKER

Christophe Bourdon came to be CEO of LEO Pharma in 2022, where he was tasked with the massive assignment of transforming the financially failing company into a success. Luckily, he had gained experience in roles of increasing leadership importance in many EU biotech companies, Sanofi, Amgen, and Alexion, as...

We’re in Munich 🇩🇪 with Cristoph Broja, Partner at EQT Life Sciences, the top venture capital firm in Europe.We talk about his lessons up until becoming a partner at the firm. We also talk about how to invest in hot areas such as obesity or ADCs, and the importance of being curious.

⭐️ ABOUT THE SPEAKER

Cristoph Broja has been a Partner at EQT Life Sciences since 2022. Prior to this, he found himself in a myriad of biotechs, such as being part of the investment team of the Boston-based Gurnet Point Capital, as well as B-F...

We’re in Munich with Philipp Baaske, one of the best life science tool founders in Europe.

We talked about the lessons of building this life science tools business, specialized in protein interactions. We also talked about the difficulties and rewards of entrepreneurship and the impact of life science tools.

___

This episode is sponsored by NanoTemper Technologies, which performs protein characterization. Learn more at https://bit.ly/flotbio_nanotemper

___

⭐️ ABOUT THE SPEAKER

Philipp Baaske, a German bi...

We’re online 🇸🇪 with Mathias Uhlen, one of the best entrepreneurial scientists in Europe.

We talked about the entrepreneurial mindset in academia. We also talked about AI for biology and why he doesn’t believe in the current anti-ageing drugs.

⭐️ ABOUT THE SPEAKER

Looking at the career of Mathias Uhlen can only leave you feeling impressed. He has co-founded or invested in 26 startups while having published over 800 papers, and creating the Human Protein Atlas, one of the most successful biology projects ever. He was also the Founding Director of Scie...

We’re online 🇫🇷 with Thomas Ybert, the co-founder of DNA Script, the leading biotech for DNA printing of oligos.

We talked about the commercialization of the first DNA printer. We also talked about company building at large and how to expand to the US successfully.

⭐️ ABOUT THE SPEAKER

At just 30 years old, Thomas Ybert co-founded DNA Script in 2014 in Paris. Previously he worked in R&D at Sanofi before joining Total in the New Energies Division where he contributed to the bio jet-fuel project in collaboration with Amyris. It was...

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's.

We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech.

— — —

Thank you to today’s sponsor, Turbine, who is organizing a free Techbio event at JPM25 and is inviting you to join. Click the link to RSVP and secure one of the limited spots:

https://www.turbin...

We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years.

We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China.

⭐️ ABOUT THE SPEAKER

Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the company and global expansion through business development and product commercialization. Prior to BioNTech Sean worked in top companies such as GlaxoSmithKline, Pfizer, Evotec, and Lorantis...

In our first episode recorded live in front of an audience, we’re with Lovisa Afzelius, the General Partner of the European branch of Flagship Pioneering 🇸🇪We talk about Flagship, including its EU activities. We also talk about company-building and Lovisa’s personal journey to be one of the leading Swedish leaders in biotech.⭐️ ABOUT THE SPEAKERLovisa is an icon in the EU biotech and pharma world, having been a CEO, co-founder, president, board chairman, and executive director in many emerging companies. Joining Flagship in 2020, she became the founding CEO of Alltrna, and co-founded/CEO of Apriori Bio, Metaphore Biotechnologie...

We’re in Budapest with Szabolcs Nagy, the founder of Turbine, one of the leading companies for AI in biotech in the world.We talked about AI in biotech at large. We also cover the differences between opening a platform versus doing proprietary drug development and building the company from central Europe. __This episode is sponsored by Turbine, which can improve your drug development. Learn more at https://shorturl.at/w3Im6__⭐️ ABOUT THE SPEAKERI’ve known Szabolcs since 2017 when he joined Bayer’s accelerator in Berlin. I found him incredibly inspiring back then and still to this day. Szabi began...

We’re online with Adrian Rawcliffe, the CEO of Adaptimmune, the TCR cell therapy company behind the first engineered cell therapy for solid tumors that was approved for a rare form of sarcoma. We talked about Tecelra's commercial rollout. We also talked about what's next in cell therapy, and Philly Cheesesteak vs Fish and Chips. — — — Thank you to today’s sponsor, Merck, who can support your antibody drug discovery. Learn more and claim a cool antibody pin here: https://bit.ly/3AhZFUA — — — ⭐️ ABOUT THE SPEAKER Adrian Rawcliffe has been in the biopharma industry for over 20 years and has worked in high positions for...

We’re in Basel 🇨🇭 with the CEO of Nouscom, one of the top EU immuno-oncology biotechs in the cancer vaccine space, Marina Udier.We talked about cancer vaccines and Nouscom’s platform. We also discussed the importance of focus for success and her career.⭐️ ABOUT THE SPEAKERMarina was recommended to me by one of her investors. She has an inspiring story, growing up in Croatia, going to the US, and making it all the way to be one of the 11% of female CEOs of biotechs in Europe in 2024. Now she is the CEO of Nouscom, but prior she was the Operating Pr...

We’re in Munich 🇩🇪 with the founder of one of the 15 most valuable European biotechs, Harpreet Singh.We talked about the field of PRAME receptors, TCR therapeutics and cell therapy at large. We also talked about the combination with mRNA therapeutics and his upbringing in a Sikh family in Germany.

🔗 LINKS MENTIONED

Labiotech.eu | “Interview Harpreet Singh - Why Being in a New Field From the Start Can Pay Off in the Long Run”, Sep 2019: https://www.labiotech.eu/expert-advice/interview-singh-immatics/

Flot.bio | “Bahija Jallal, Immunocore 🇬🇧 | Commercial, Diversity, and AI | E14”, Mar 2024:https://www...

We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis. We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success.

💎 ABOUT THE SPEAKER

Dominik has had an incredible career, which he started from a young age. With the founding of Tubulis, he has w...

We’re in Boston 🇺🇸 with one of the top VCs, Otello Stampacchia of Omega Funds. We talked about the highest competitive tension in biopharma now that he has ever seen. We also talked about his career, especially the challenges and opportunities he had from moving to Boston over 15 years ago.

💎 ABOUT THE SPEAKER

Otello is the founder and managing director of Omega Funds which he started in 2004. As an investment guru, he leads the investor relations and strategic initiatives. Previously Otello led the fund investment of one of the largest private equity asset manager...

We’re in San Sebastián 🇪🇸 with one of the top VCs in Europe, Christina Takke from V-Bio Ventures.

We talk about her path to get to the top and the benefits of gender diversity for both investing and European biotech as a whole. We also talk about her investment in Argenx when it was only three employees and the venture creation had dropped since 2022.

💎 ABOUT THE SPEAKER

Christina co-founded V-Bio Ventures in 2015 and is now the Managing Partner. Before this, she was a leader in the European Ventu...

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings.

We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. I’ve known him since he was a partner at Andera. He is a sharp investor, but also very friendly and open.

💎 ABOUT THE SPEAKER

Naveed has been a part of Novo Holdings since 2019 and splits his time between London and Copenhagen. He has over 25 years o...

We’re in Hannover 🇩🇪 with the founder and CEO of Cardior, Claudia Ulbrich

We talked about Cardior’s recent €1B exit to Novo Nordisk. We also talk about miRNA and Cardiovascular, and why she earned the funny nickname “Frau Biotech”.

💎 ABOUT THE SPEAKER

Claudia has been founding biotechs since the ’90s. She founded her first biotech company, LipoNova AG in 1998 and went on to co-found many more, including Cardior Pharmaceuticals. During her time she has launched and brought public a cancer vaccine company, helped see through a multi-million dollar deal of over €20M, and much more.

...

We’re super privileged to chat online with Bahija Jallal, the CEO of Immunocore. Immunocore is the largest biotech in the UK and the 5th largest in Europe with a market cap of just over 3 billion dollars. We talk about how Immunocore has helped thousands of cancer patients and has become a commercial biotech. We also talk about why she thinks gender and race diversity are a business case and how AI is changing protein and biologics engineering. 💎 ABOUT THE SPEAKERI’ve “known” Bahija for over 10 years, after reading her profile in a student pharma magazine when I was studying bi...

We’re in Brussels with Edwin Moses, the former CEO of one of the most successful platform companies in Europe, Ablynx, now part of Sanofi. We talk about how he feels 5 years after the exit from Ablynx and his lessons. We also talk about the parallels between industrial biotech, AI bio and cell therapy, and how a chairman can help CEOs grow.

💎 ABOUT THE SPEAKER

Edwin Moses is Chairman of Achilles Thx (cell therapy for solid tumors), Avantium (bioplastics) and LabGenius (AI biotech). He is the former CEO of one o...

We’re in Copenhagen with Jens Nielsen, the CEO of BioInnovation Institute. We will talk about what works best to translate academic research in bio into innovation for humanity, especially how everything is connected. We also talk about how BII is solving some of the main challenges scientist entrepreneurs face and the drawbacks of Novo financing most of Denmark’s biotech ecosystem. 💎 ABOUT THE SPEAKER Jens Nielsen is one of the best in this space in Europe. Not only is he the CEO of BII, he’s also a professor of systems biology at Chalmers University of Technology in Sweden, a...

We’re in Amsterdam with Sander van Deventer, the CEO of VectorY. We will talk about VectorY and what’s missing in gene therapy. 💎 ABOUT THE SPEAKER Sander has an impressive track record, being a professor, operational biotech founder and a VC. In 1998, he co-founded uniQure, which brought the first gene therapy to the market. He also co-founded the leading VC Forbion as well as Dezima. He is now building a new venture VectorY, again in gene therapy. I interviewed him in 2017 back at Labiotech so it’s great to catch up with him again. 📜 TRANSCRIPT Read the full transcript h...

In an online special, we’re interviewing Thomas Clozal, the co-founder and CEO of Owkin. We talk about scaling AI in biotech and how it feels to be the child of billionaire biotech parents.💎 ABOUT THE SPEAKERThomas founded Owkin in 2016 and I first met him in 2017. At that time, Owkin was still a baby and I wasn’t sure where it would go. Now it’s a unicorn following a $180M investment from Sanofi in 2021 and has over 300 employees. 🔗 LINKS MENTIONED - Exscientia Expands Biologics Design Capability with Automated Laboratory https://investors.exscientia.ai/press-releases/press-release-details/2022/Exscientia-Expands-Biologics-Design-Capability-with-Automated-Laboratory/default.aspx- Marc de Gari...

Today, I’m in Paris (🇫🇷) to chat with Marc de Garidel, the new CEO of Abivax. We talk about the challenges behind the exits and why Abivax could be a third big success. 💎 ABOUT THE SPEAKER Marc is a biopharma veteran with an impressive track record. He has made two billion-dollar exits, was CEO of Ipsen, and has recently made the biggest French IPO ever with Abivax. He has also raised $60M series B for Massachusetts-based Corvidia Therapeutics before being acquired for $2.1B by Novo Nordisk. He also was the CEO of CinCor Pharma which sold for $1.8B to AstraZeneca...

Today we're in Munich at BIO-Europe to chat with one of the best commentators in European biotech, Mike Ward. We talk about the best and the worst of the European biotech industry since the 80s. 💎 ABOUT THE SPEAKER Mike has been in biotech content since the birth of the industry in the 80s. He has worked at BioCentury, Informa/Scrip and now Clarivate. I’ve known Mike for many years and I like how clearly he sees things while being no-bullshit and fun. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/y428h2wr 🫶 FOLLOW US - Newsletter: http://eepu...

We’re live from Oslo 🇳🇴 to catch up with Agnete Fredriksen, co-founder and CBO of Nykode (ex-Vaccibody). In this episode, we chat about being one of the leading women in bio in Europe, the Nordics, and immunotherapies. 💎 ABOUT THE SPEAKER Agnete founded the immunotherapy company Nykode in 2006 which is now worth around $500M. For her PhD she designed and developed the first Vaccibody vaccine molecules, improving the outlook for cancer patients. I’ve known Agnete for many years and I like her sharpness while having this Scandinavian humility. 📜 TRANSCRIPT Read the full transcript here: https://tinyurl.com/yk364wes 🔗 FOLLOW US - Don't mi...

Biotech great Rodger Novak, Co-Founder and Chairman of CRISPR Tx joins us on the show. In this episode, we chat about bringing the first CRISPR drug to the market and why he thinks everything is wrong in bio in Europe besides science. Rodgers’ is a name everyone should know, having made it big in the global biotech scene. I first interviewed him back in 2016 at Labiotech. It’s a treat to be able to sit down with him again.

💎 ABOUT THE SPEAKER A serial entrepreneur, Rodger Novak has made it big through his many successful enterprises in the pha...

We’re back live and in Paris 🇫🇷 with our next guest, Johannes Fruehauf. We talk about reinventing the co-working labs for biotech startups, the difficulties of doing business in Europe, profitability in biotech, and much more (see timestamps below).

💎 ABOUT THE SPEAKER

Johannes is the President, CEO, and founder of BioLabs, the biggest “incubator”, or as they like to call it “co-working laboratory”, platform for biotech startups in the world. Today they have over 14 locations, including 3 in Europe (2 in Paris and 1 in Heidelberg). He is also the founder of LabCentral and a general partner at...

In a virtual special, we welcome Bernat Olle to the show. We discuss the microbiome space, including Vedanta’s upcoming Phase 3, and how it feels to be a European founder in Boston.

Bernat is the CEO and co-founder of Boston-based Vedanta Biosciences, one of the leading microbiome companies. They’ve had a positive Phase 2 trial and recently raised a $107M round to run a Phase 3.

Bernat is a life science trailblazer. During his doctorate at MIT, he developed a novel method for large-scale bacterial culture. He's been named "Innovator of the Year in MIT...

It’s a treat to welcome Ingmar Hoerr on the show. We chat about building a 20B dollar biotech startup, almost dying on the job, and why people skills are so important in biotech. 

Ingmar is a pioneer in the EU biotech scene, revolutionizing drug development with mRNA therapeutics. He and his team created the initial technology used in mRNA vaccines and submitted the first patents for its use. CureVac helped other mRNA companies such as Moderna and BioNTech successfully solve the Covid pandemic. Ingmar is very inspiring, as he is visionary and bold whi...

It's great to have Werner Lanthaler, the CEO of Evotec, one of the largest biotech research companies in Europe/the world, on the show. We have known each other for almost ten years now. He's not only sharp but also friendly and easy to talk to. In this episode, we chat about leading AI in biotech, the sharing economy in the industry, how to be authentic, and more. Hope it helps you learn, be inspired and grow 😉

📯 MENTIONED- Fireside chat with Werner talking about AI in Biotech in 2019 at BIO-Europe Spring in Vienna - https...

For our first episode, we catch up with Antoine Papiernik, the chairman of Sofinnova partners, one of the top EU biotech VC funds. We chat about building billion-euro biotechs in Europe, being listed on the Midas list (without letting it go to your head), the importance of being good at selling, being lucky, and how to balance all this with family priorities.

I've been lucky to know and be inspired by Antoine for almost 10 years. Over his successful career, he has invested in over 500 companies, focusing on platform companies and entrepreneurs. He currently has over €2.5 billion un...